Bio-Techne Scoops Up Genetics And Oncology-Focused Diagnostics Firm

  • Bio-Techne Corp (NASDAQ: TECH) has agreed to acquire Asuragen Inc, a provider of genetic carrier screening and oncology testing kits.
  • The deal value includes an initial consideration of $215 million in cash plus contingent consideration of up to $105 million.
  • The transaction will close by the end of this year.
  • Bio-Techne had a cash, equivalents, and short-term investments balance of $282.95 million as of December 2020.
  • Asuragen operates a 50,000 square foot manufacturing facility and a laboratory. Last year it generated greater than $30 million in revenue globally.
  • Asuragen's CEO, Matt McManus, will join the Bio-Techne team to continue to lead the legacy Asuragen business and the integration process.
  • Perella Weinberg Partners LP is the financial advisor, and Vinson & Elkins LLP is serving as legal counsel to Asuragen.
  • Price Action: TECH shares closed 3.8% lower at $361.24 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&ANewsHealth CareGeneralDiagnostics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!